APPLICATION
ANDA091123
TYPE
ANDA
ORIGINAL APPROVAL
2011-07-11
LATEST ACTION
2016-02-02
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
2016-02-02Labeling · Supplement 6 · standardAP
2016-02-02Labeling · Supplement 4 · standardAP
2016-02-02Labeling · Supplement 5 · standardAP
2014-01-10Labeling · Supplement 3 · standardAP
2012-10-16Labeling · Supplement 2 · standardAP
2011-07-11OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.